James N. Kochenderfer

James N. Kochenderfer is the inventor of the first BCMA-targeted CAR-T cell therapy for multiple myeloma. His 2013 CAR design was licensed to bluebird bio and developed as idecabtagene vicleucel (Abecma), approved by FDA in March 2021. His first-in-humans trial (JCO 2018) demonstrated 81% response rate in heavily pretreated myeloma. Previously, his anti-CD19 CAR design was the first to demonstrate clinical activity in humans (Blood 2010), contributing to development of FDA-approved CD19 CAR-T products. He received the 2019 FNIH Trailblazer Prize for Clinician-Scientists and a 2020 Clinical Research Forum Top 10 Achievement Award. With 153 publications and 31,502 citations, Kochenderfer represents successful federal research leading to multiple FDA-approved cellular therapies.

James N. Kochenderfer博士是首个针对多发性骨髓瘤的BCMA靶向CAR-T细胞疗法的发明者。他2013年的CAR设计被授权给bluebird bio并开发为idecabtagene vicleucel（Abecma），于2021年3月获FDA批准。他的首次人体试验（JCO 2018）在重度预治疗骨髓瘤患者中展示了81%的缓解率。此前，他的抗CD19 CAR设计是首个在人类中展示临床活性的（Blood 2010），促成了FDA批准的CD19 CAR-T产品的开发。他获得2019年FNIH临床科学家开拓者奖和2020年临床研究论坛十大成就奖。凭借153篇出版物和31,502次引用，Kochenderfer代表了联邦研究成功转化为多个FDA批准细胞疗法的典范。